June 1, 2024Journal of Clinical Oncology

Outcomes of rituximab as treatment for immune thrombocytopenic purpura in patients who have failed steroids or IVIG: A retrospective study in a community practice.

View Full Paper

Ask AI

Bookmark

Authors

WKWissam KaramUniversity of Kansas AAAnas AlqamUniversity of Kansas RARyan AshkarIndiana University Health

Discussion

Member takes

Implication

Retrospective study demonstrates high response rates to rituximab in immune thrombocytopenic purpura, suggesting its viability as a cost-effective second-line therapy.

Key Points

Platelet response reached 96.7% following rituximab therapy in patients with immune thrombocytopenic purpura, although 46.7% experienced subsequent disease relapse.
Retrospective study of 60 eligible adults evaluated platelet counts after four doses of rituximab alongside salvage responses to thrombopoietin receptor agonists.
Highlights rituximab as an effective second-line option for refractory disease, which preserves high efficacy for sequential thrombopoietin receptor agonists.

Cite This Study

Karam et al. (2024) studied this question.

synapsesocial.com/papers/68e66f03b6db6435875fa206 https://doi.org/10.1200/jco.2024.42.16_suppl.e23256

View Full Paper

Ask AI

Bookmark

Implication

Retrospective study demonstrates high response rates to rituximab in immune thrombocytopenic purpura, suggesting its viability as a cost-effective second-line therapy.

Outcomes of rituximab as treatment for immune thrombocytopenic purpura in patients who have failed steroids or IVIG: A retrospective study in a community practice.

Discussion

Member takes

Implication

Key Points

Cite This Study

Outcomes of rituximab as treatment for immune thrombocytopenic purpura in patients who have failed steroids or IVIG: A retrospective study in a community practice.

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider